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Abstract  
Pooled analysis of individual patient data from stroke trials can deliver more precise 
estimates of treatment effect, enhance power to examine pre-specified subgroups, and 
facilitate exploration of treatment-modifying influences. Analysis plans should be 
declared, and preferably published, before trial results are known. For pooling trials 
that used diverse analytic approaches, an ordinal analysis is favoured, with 
justification for considering deaths and severe disability jointly. Since trial pooling is 
an incremental process, analyses should follow a sequential approach, with statistical 
adjustment for iterations. Updated analyses should be published when revised 
conclusions have a clinical implication. However, caution is recommended in 
declaring pooled findings that may prejudice ongoing trials, unless clinical 
implications are compelling. All contributing trial teams should contribute to 
leadership, data verification, and authorship of pooled analyses. Development work is 
needed to enable reliable inferences to be drawn about individual drug or device 
effects that contribute to a pooled analysis, versus a class effect, if the treatment 
strategy combines two or more such drugs or devices. Despite the practical 
challenges, pooled analyses are powerful and essential tools in interpreting clinical 
trial findings and advancing clinical care. 
 
 
 
  
Background 
Scientific advancement is based on hypothesis testing and replication. Clinical trials 
are interpreted on this basis: a single positive trial may be encouraging for any new 
therapy but two such trials are typically required for marketing authorisation and 
establishment into clinical practice. For many reasons, that may include insufficient 
statistical power, suboptimal design, inexperience with treatment delivery, and use of 
prototype treatment approaches, initial clinical trials of a useful treatment may declare 
a falsely neutral result; however, publication bias also contributes to the trend for later 
trials to be positive. It has become recognised practice to pool trials to refine our 
assessment of the treatment effect, helping to indicate not just whether it is effective, 
but also how effective it may be, and in which circumstances. 
 
Typically, data are pooled at the trial level (i.e., meta-analysis) or, occasionally, at the 
subgroup level. For example, the Cochrane review of thrombolysis for acute 
ischaemic stroke management used trial-level data for its main analysis and 
considered two treatment time windows for subgroup analyses.  While this type of 
trial-level pooling is useful, it disregards potentially valuable information at the 
patient level that could prevent false conclusions. Taking the principal results of the 
Cochrane thrombolysis review, a reader may conclude that use of iv alteplase is 
justified only if administered within 3 hours of stroke onset, since the 3-6 hour 
subgroup analysis showed no significant benefit; or that treatment at any time within 
6 hours is justified, since the primary analysis of the 0-6 hour data was positive.
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Conversely, a reader of the pooled analysis of individual patient data (IPD) would 
likely draw a different conclusion: seeing that treatment benefit is closely dependent 
on delay since stroke onset, and that benefit remains statistically significant until at 
least 4.5 hours, the reader may favour treatment beyond 3 hours but only until 4.5 
hours. 
 
Pooling of IPD also opens the way for more powerful analyses, since results can be 
adjusted for multiple covariates (e.g., time to treatment, age, stroke severity, sex, 
diabetes, prior stroke, and baseline neuroimaging features in the setting of 
thrombolysis trial data). Exploration of individual covariates in larger samples allows 
for a better estimate of treatment effect size in future populations and subgroups, 
restricts the confidence interval around these estimates, and indicates which are the 
important factors to consider when selecting patients for treatment. The analysis of 
pooled IPD releases the restrictions imposed by the individual trial protocols and 
publications:  fresh criteria for defining subgroups and applying a common outcome 
measure become possible.  Furthermore, subgroup analyses that are pre-specified (i.e., 
prior to release of trial results) and adequately powered could go beyond being 
hypothesis-generating to achieving a new level of evidence.  Individual trials may be 
underpowered to assess a given subgroup and, in that circumstance, a pooled analysis 
might bring key confirmatory data for regulatory considerations. It is acknowledged 
that in addition to prespecifying subgroups of interest, pooled analyses must still 
protect against the risks inherent in multiple testing by prespecifying the primary 
endpoint and incorporating statistical adjustment where necessary. 
  
These advantages of IPD carry a modestly greater burden, however. Cooperation 
among trialists is required and needs to be coordinated; the necessary technical skills, 
time, effort and costs are increased; it is essential to understand and allow for the 
varied context and conditions under which data were collected across trials; and the 
risks of data mining become infinitely greater. 
  
This manuscript describes conclusions arising from a workshop held at the ninth 
Stroke Academic Industry Roundtable (STAIR) on 5 October 2015 in Bethesda, USA. 
This workshop was designed to discuss principles that would facilitate and optimise 
value from pooling of stroke trial data. Participants included academic, industry and 
regulatory experts are listed in the Appendix. The approach taken to develop STAIR 
guidelines has been described elsewhere.
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 Key recommendations are summarized in 
the Table. 
 
Outcome measure selection 
Though most acute stroke trials have chosen the modified Rankin Scale (mRS) as 
their principal outcome measure, and those that instead targeted vessel patency have 
retained mRS as a secondary measure, several analytic approaches and definitions of 
good results have been used.  For example, these have included dichotomising 
modified Rankin at 0-1 versus 2-6, at 0-2 versus 3-6 or even at 0-4 versus 5-6; 
examining a ‘shift’ in distribution of the full scale or examining the distribution after 
combining category 5 (bedbound) with 6 (dead); or finally examining patient-centred 
‘utility’ of the mRS scores, which has a similar effect as the previous approach. 
(Figure) Each has merit, but a pooled analysis may have different aims from 
individual RCT objectives. A common approach is needed when combining trials, if 
the influence of covariates is to be correctly estimated. Since switching the choice of 
endpoint may change the formal interpretation of the trial between neutral and 
positive, and since a common endpoint likely will not already exist, the collaborators 
planning a pooled IPD analysis must take care when pre-specifying their endpoint.  
 
If none of the trials to be included has already been unblinded, then any rational 
approach to analysis may be justified. If, however, one or more trial results were 
known, then this would influence or be perceived as influencing the choice of 
common endpoint. The least restrictive approach is needed (i.e., the one that invokes 
fewest assumptions). It must still be an endpoint that is rational for the treatment 
being tested and useful for clinical interpretation. The available choices each have 
pros and cons. 
 
Dichotomisation considers the mRS in only two categories, such as mRS 0-1 as good 
outcome and mRS 2-6 as bad outcome. This endpoint can readily be used to assess 
statistical significance and to generate a measure of effect size with an associated 
confidence interval; can be converted easily to a number needed to treat (NNT); and 
is simple to explain to patients and clinicians.  However, it also suffers from three 
disadvantages. First, it may conceal harmful effects within the ‘poor outcome’ 
stratum:  for example, an increase in mortality due to increased intracranial bleeding. 
This separates benefit from risk. It may be desirable to do so, particularly if the 
timescale for these two differs, such as when fatal bleeding due to treatment may be 
somewhat balanced by later survival gains among the less disabled survivors of 
treatment. Second, for many stroke trial populations, it also conceals benefits among a 
majority of patients who participated and were destined at best to achieve partly 
disabled survival (mRS 2, 3 or 4). It is neither ethical to include such patients if they 
will not contribute usefully to interpretation to the trial, nor is it statistically sensible 
to disregard the richness of the information that they provide; indeed, an ordinal 
approach to analysis typically contributes 36% more information and thus statistical 
power than a dichotomised approach.
3
 Third, dichotomisation requires a combination 
of advanced knowledge of the treatment’s effects, the case mix of the trial, and luck.   
Without these, the chosen cut point for dichotomisation may turn out to show a 
smaller treatment effect than other thresholds that have been disregarded. Although 
this has been discussed in the stroke literature, several recent trials retained 
dichotomization of primary endpoints and reported neutral results, whereas they 
would have declared positive results if different cut points or ordinal analyses had 
been selected as favoured by the European Stroke Organisation Outcomes Working 
Group.
4-6
 
 
An ordinal approach also invokes certain assumptions and requires some choices, 
however. The first assumption of ordinality is that each step on the scale reflects a 
genuine improvement from the preceding step, as perceived by all relevant parties.  
This may not be universally accepted for mRS, because in some societies and among 
certain age groups, survival with severe disability – bedbound, incontinent and totally 
dependent (i.e., mRS 5) – is considered to be as bad as or even worse than death.7 
This creates an argument for combining mRS categories 5 and 6 in an ordinal analysis 
approach.
8
 The second assumption, which has less importance and which does not 
compromise statistical analysis but has an impact on presentation of results, is that all 
steps are of equal value (i.e., assumption of proportionality). It is evident that this 
assumption is violated for mRS:  many patients regard the steps between mRS 5 and 4 
(being released from bed) and from 4 to 3 (recovering independent mobility) as 
carrying greater value than returning to all usual activities (mRS 2 to 1) or being free 
from non-disabling symptoms (mRS 1 to 0). Describing a trial result by showing 
average improvement of a certain proportion for each mRS category is complex. The 
statistical approaches to ordinal analysis suffer from some disadvantages also. The 
usual non-parametric approach to testing for an overall difference in distribution that 
favours one treatment over the other, the Cochran-Mantel-Haenzsel test, permits 
adjustment for covariates in its van Elteren variant. However, it requires these 
covariates to be categorical rather than continuous, so that age and stroke severity 
each must be grouped. It provides a p value but expresses neither the direction of 
change nor the size of effect.  It typically is followed by ordinal logistic regression to 
estimate the odds ratio of the treatment effect and its associated confidence interval.  
This second step introduces an assumption of proportionality of odds – implying that 
the treatment has changed the odds of moving from mRS 5 to mRS 4 by a similar 
amount to the odds of moving from mRS 3 to 2, etc. This assumption has been 
violated when examining thrombolysis treatment for acute stroke.
9
  (Lees, 
unpublished data, 2016) It also creates a second problem:  the logistic regression 
generates its own p value associated with the estimated confidence interval for the 
odds ratio, and that p-value generally differs slightly from the overall p-value 
calculated from the van-Elteren test.  However, logistic regression permits use of both 
continuous and categorical covariates. Even so, there are several approaches to 
describing the effect size that do not invoke the proportionality assumption
10-12
 and 
also several circumstances where any violation of the assumption has limited impact. 
 
A further variation in ordinal approach is to adjust the weight given to mRS 
categories according to their perceived utility to patient groups, to multiply the 
number of patients within each mRS category by that utility weight, and then to 
analyse the sum of these products by a parametric test.
13,14
 This approach solves 
several of the weaknesses of the earlier methods but its main disadvantages are that 
social, geographical and demographic factors may influence the weights given to 
mRS categories, and that some disabilities such as dysphasia cannot be ranked 
because many stroke survivors with dysphasia cannot respond to such surveys.  
 
In considering all of these issues, the STAIR workshop participants concluded that a 
standard methodology for pooled analyses would be desirable, and an ordinal 
approach should generally be favoured for an IPD pooled analysis where there was 
prior variation in chosen endpoint among contributory trials, because this had greater 
statistical power and reduced reliance on assumptions around the nature of the 
treatment effect. The participants also favoured collapsing mRS categories 5 and 6, 
since this better reflected perceived value of the steps. Although there was 
considerable enthusiasm for the utility-weighted approach, it was considered still to 
be less validated and subject to geographic or cultural biases. The participants noted 
that, though an ordinal approach for distribution of mRS (where mRS 5&6 are 
combined) should be the primary approach, results should also be converted to the 
utility-weighted and dichotomised approaches for descriptive purposes. Finally, they 
noted also that their conclusion should not restrict the analytic approaches of 
individual trials, where different considerations may apply. 
 
A pooled IPD analysis must also harmonise the timing of final assessment used for its 
principal analysis, though the choice here is less controversial, less under control of 
the trialists and possibly may have less impact on interpretation. The latest common 
assessment that is available in all trial datasets should be used, recognising the usual 
convention that recovery is unlikely to have stabilised before 3 months. For example, 
the stroke thrombolysis trialists’ collaboration chose to accept outcomes at 3 months 
for 8 trials, but at 6 months for a ninth trial in their pooled analysis, rather than 
describe outcome at one month or earlier.
15
  
 
Repeated analyses / publication 
Just as interim analysis of a single trial for efficacy or futility influences the 
probability of reaching a final positive result and thus requires reduction of the final p 
value for significance, assimilation over time of trial datasets to a pooled IPD analysis 
must be recognised as a sequential approach. Even if the protocol for a pooled 
analysis were published in advance of unblinding of any of its contributory trials, 
specifying the number, size and identity of the trials that will be included before a 
result will be announced, it is conceivable that a further trial will be created later to 
extend, confirm or refine some aspect of its findings. Pooled analysis is a continual 
process. The participants at STAIR recommend that a sequential analysis approach be 
taken to control for the potential bias generated when analysis may be undertaken 
repeatedly, on an expanding sample. The statistical analysis plan for the TREAT 
collaborators’ pooling of the thrombectomy trials describes an appropriate approach.8  
Bayesian approaches were also suggested, and further work in this area is needed to 
consider the advantages of one over the other.. 
 
This requirement to adjust for potential repeated looks at the data applies not just to 
an overall result from the pooled analyses (is treatment effective or not?); it also, 
perhaps more importantly, applies to subgroups, which likely will expand at different 
rates since trials vary in their case mix.  Further, for subgroups especially, a sample 
size calculation should be described. This need not restrict analysis prior to attainment 
of that sample, but will assist in interpretation of neutral findings for such subgroups.  
Again, the TREAT statistical analysis plan covers both issues.
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Third, due to variations including trial design, timescale, geographical location, there 
will be likely variation in treatment effects that cluster within trials. Pooling IPD 
allows powerful analyses of individual factors that contribute to variation but the 
analysis approach should still stratify by trial to control for possible heterogeneity 
between trials. This was done by the STTC and is planned by TREAT investigators.
8.9 
 
The sequential nature of such pooled IPD analyses leads to a question over timing of 
publication of results. There are arguments in favour of lodging such papers in an 
accessible online repository each time that they are updated, but the STAIR 
participants recommend that formal publication in a peer review journal be considered 
each time that a fresh analysis produces a finding that may change clinical 
management.  Reporting should follow PRISMA-IPD recommendations.
16
  
 
Regulatory issues 
There may be conflict regarding pooled outcomes as a group treatment effect (e.g., 
thrombectomy by any reasonable means improves outcome) versus specific device- or 
drug-specific effects (e.g., thrombolysis via rtPA but not streptokinase is effective). 
There is a need to define circumstances in which the scientific community, and 
regulators, should accept a group effect. This may be reasonable if each component 
drug or device in isolation shows a point estimate for effect above a certain threshold, 
but it is uncertain whether absence of significant heterogeneity is sufficient. In 
circumstances of a new treatment, a non-inferiority analytic approach may be taken.  
This could be extended to allow for a drug-by-drug (or device-by-device) comparison 
of individual effects against the pooled effect of the remaining treatments.  There is a 
need for development work in this area, to consider technical aspects and to formulate 
guidance on managing such exploratory analyses. 
 
It would be ideal if the planned interpretation in this regard were published in advance 
of any trial result being known, and certainly preferable that it should be decided in 
advance of any pooled analysis.  If plans are not prespecified, then any heterogeneity 
within the result will need cautious interpretation.   
 
Sharing of data 
Ideally, all datasets would be collected in a common format and would be shared 
immediately upon conclusion of each trial. In practice, neither is realistic. Trials are 
individually designed and require time to publish individual primary and secondary 
results. Common data elements for NINDS trials have been defined elsewhere
17
 but 
are variably observed.  Data are stored and shared in varied formats using diverse 
definitions for each variable. A substantial part of the work of pooling involves 
understanding each trial properly. This requires a skilled, stroke-experienced 
statistician working in close collaboration with the original investigators of each trial. 
These original investigators should also meet and collaborate actively in the writing 
of protocols for pooled analysis and in the interpretation of findings. The trial 
protocols, statistical analysis plans, manuals of procedures and case report forms 
should be shared to aid interpretation of the dataset. It is not sufficient to send a file 
with data to the pooling group and hope that they will correctly understand the 
documents from an individual study. 
 
The timing of data sharing presents another challenge. Trial investigators must have 
an opportunity to present and publish the primary and planned secondary analyses of 
their study without compromising this intellectual property by releasing raw data to 
the public domain or having the research questions answered from a pooled source 
beforehand. The pooling collaboration should be able to offer firm guarantees that 
shared data will be used only for the approved pooled analyses and will not be 
released to a third party without prior agreement, and that the pooled analyses that 
compete with the trialists’ existing plans will not be released in advance of their 
individual publication.  At some later point, these issues become less relevant, 
particularly for government-sponsored and investigator-initiated trials.  For example, 
NIH-funded clinically trials are required to have data-sharing plans upon initiation to 
ensure “timely” release of data to the public.18 More broadly, the Institute of Medicine 
recommends public release of data associated with the primary publication of the trial 
results within six months of primary publication, and the full data set no longer than 
18 months after study completion (unless the data are part of a regulatory 
application).
19 
Even so, the STAIR participants recognised that IPD analyses should 
be undertaken as a joint, collaborative venture for scientific as well as political 
reasons, and these rules about data do not directly guarantee cooperation. 
 
More complex is the situation in which a pooled dataset may already answer a 
question that is being tackled specifically by an ongoing or planned trial, and may 
thereby compromise completion of that trial. For example, an analysis of IPD from 
recently published thrombectomy trials may indicate an apparent relation of treatment 
benefit to time elapsed from stroke onset.  At the same time, ongoing trials are 
examining late time windows.  The pooling collaborators must consider the merits of 
such cases, taking into account the relative size of the datasets, the timescale over 
which the ongoing trial(s) may be completed, the clinical impact of any early 
announcement and the ethical dimension.  Potential conflicts of interest among 
investigators must be handled carefully. These questions are similar to issues that 
regularly face independent data monitoring committees. 
 
A collegiate spirit and recognition of colleagues’ contributions and concerns is also 
required for leadership and authorship purposes. Pooling projects require 
representation from every contributing trial. These representatives should ideally be in 
place even during the planning phase, though there must be a mechanism to add 
contributors when new trials become available.  It is a good principle that authorship 
should also have one or more representative from each trial that contributes data to 
the collaboration, even if a small writing group will draft the manuscripts, and it is 
desirable that the author byline should refer to each of the component trial groups, 
with a listing of their steering committees in an appendix. Pooled analyses can have 
considerable academic impact, and it would be unreasonable for the original authors 
of the contributing trials not to share in the final reports. Pooled analyses should not 
be undertaken by independent groups without full participation of the original 
trialists, for both academic and practical reasons. Some of these, for example relating 
to checks of data integrity, are reflected in the PRISMA-IPD statement.
16 
 
A further challenge arises from the contribution of funders.  Sponsorship of research 
should merit access to output from pooled analyses at an early stage but should 
neither influence the design of the analysis, the interpretation of findings nor the 
timing of publication. Handling of subsets of data and of drug- or device-specific 
analyses, as discussed earlier, may need cautious consideration if these would have 
commercial implications. 
 
Conclusions 
Pooling of individual patient data from individual clinical trials provides the power to 
determine treatment effects with more precision, especially within subgroups, and to 
explore modifiers of treatment effect.  To be unbiased, detailed analysis plans should 
be declared before trial results are available. An ordinal analysis with a sequential 
approach, with statistical adjustment for each iteration, is favoured. All contributing 
trial teams should contribute to leadership, data verification, and authorship of pooled 
analyses. With careful planning and collaborative approaches, pooled analyses can 
meaningfully and rapidly advance clinical care for our stroke patients by providing 
supportive data and new observations. 
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Figure Legend.  Each pair of stacked bars represents the same trial outcome, with 
proportion of patients achieving best outcome (mRS 0) on the left and worst outcome 
(death, mRS 6) to the right.  The top 3 sets illustrate dichotomisation approaches, in 
which mRS categories are grouped for analysis purposes, ie red is compared to blue.  
The lower 3 sets show methods of ordinal analysis, where all, or most, categories are 
considered independently. The 6
th
 set illustrates the impact of applying a utility-
weighted approach to the mRS strata for the same trial. 
 
 
 
  
Figure:  Schematic illustration of analysis approaches to modified Rankin scale 
(mRS) in stroke trials. 
 
 
 
  
Table:  Summary of Key STAIR IX Recommendations for Individual Data Pooling 
Analyses of Acute Stroke Clinical Trials 
 
TOPIC Recommendation Rationale/Comments 
Analysis Plan 
Prespecification 
Declare analysis plan 
prior to completion of 
trials to be included in 
primary analysis 
Eliminates bias associated with 
knowledge of results of first trial(s). 
Potentially enables level of evidence 
beyond hypothesis generation. 
Outcome Measure 
Selection/Analysis 
Use ordinal analysis 
modified Rankin score 
as primary endpoint  
Minimizes assumptions while typically 
maximizing statistical power when 
pooling trials with diverse 
approaches/endpoints. 
Death and severe disability may be 
considered jointly.  
Repeated 
Analyses 
Use sequential 
analysis approach  
Controls for potential bias (false-
positive results) associated with 
repeated statistical testing. 
Publication 
Frequency 
Publish each analysis 
that demonstrates 
evidence for 
significant change in 
clinical practice 
Use caution in declaring findings that 
may prejudice ongoing trials unless 
clinical implications are compelling. 
Authorship All contributing trial 
teams should 
contribute to 
A collegiate spirit and recognition of 
colleagues’ contributions and concerns 
is critical. 
leadership, data 
verification, and 
authorship of pooled 
analyses 
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